Niagen Bioscience, Inc. Common Stock (NAGE) Stock Price

NAGEStock

$2.49−66.44%52W

Market Cap$198.31M

P/E11.33x

PEG Ratio—

Div yield—

Beta2.08

NAGE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-56.81%

Price vs S&P 500 (4W)-16.77%

VGM Score45.15

P/E Ratio (Annual)11.33x

P/CF (Annual)14.59x

Book Value / Share (Quarterly)$1.05

P/TBV (Annual)7.16x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)21.56%

Cash Flow / Share (Quarterly)$0.07

Price vs S&P 500 (YTD)-72.78%

Gross Margin (TTM)64.24%

Net Profit Margin (TTM)12.39%

EPS (TTM)$0.19

10-Day Avg Trading Volume0.51M

EPS Excl Extra (TTM)$0.19

Revenue Growth (5Y)16.91%

EPS (Annual)$0.20

ROI (Annual)22.71%

Gross Margin (Annual)64.28%

Net Profit Margin (5Y Avg)-9.42%

Cash / Share (Quarterly)$0.84

P/E Basic Excl Extra (TTM)12.32x

Revenue Growth QoQ (YoY)-4.28%

P/E Normalized (Annual)11.33x

ROA (Last FY)16.34%

Revenue Growth TTM (YoY)10.99%

EBITD / Share (TTM)$0.19

ROE (5Y Avg)-23.86%

Operating Margin (TTM)11.91%

Cash Flow / Share (Annual)$0.17

P/B Ratio2.39x

P/B Ratio (Quarterly)3.08x

Net Income / Employee (Annual)$148,600

EV / Revenue (TTM)1.01x

Net Interest Coverage (TTM)-451.17x

ROA (TTM)15.03%

EPS Growth QoQ (YoY)-72.01%

EV / EBITDA (TTM)8.20x

EPS Incl Extra (Annual)$0.20

Current Ratio (Annual)4.86x

Quick Ratio (Quarterly)5.00x

3-Month Avg Trading Volume0.61M

52-Week Price Return-66.44%

EV / Free Cash Flow (Annual)9.87x

P/E Incl Extra (TTM)12.32x

Revenue / Employee (TTM)$1,103,300

Tangible BV / Share (Quarterly)$0.98

P/S Ratio (Annual)1.52x

Asset Turnover (Annual)1.22x

52-Week High$7.95

Operating Margin (5Y Avg)-10.47%

EPS Excl Extra (Annual)$0.20

CapEx CAGR (5Y)15.84%

26-Week Price Return-46.91%

Quick Ratio (Annual)3.77x

13-Week Price Return-24.09%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.50x

Enterprise Value$130.44M

Revenue / Share Growth (5Y)9.32%

Asset Turnover (TTM)1.21x

Revenue / Employee (Annual)$1,106,200

Inventory Turnover (Annual)3.12x

Pretax Margin (Annual)14.06%

Cash / Share (Annual)$0.81

3-Month Return Std Dev47.83%

Gross Margin (5Y Avg)61.56%

Net Income / Employee (TTM)$136,700

ROE (Last FY)22.71%

Net Interest Coverage (Annual)-510.50x

EPS Basic Excl Extra (Annual)$0.20

P/FCF (TTM)28.43x

Receivables Turnover (TTM)14.16x

EV / Free Cash Flow (TTM)22.99x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.19

Receivables Turnover (Annual)14.78x

ROI (TTM)20.50%

P/S Ratio (TTM)1.53x

Pretax Margin (5Y Avg)-9.23%

Revenue / Share (Annual)$1.51

Tangible BV / Share (Annual)$0.89

Forward P/E21.06x

Price vs S&P 500 (52W)-81.97%

P/E Ratio (TTM)12.32x

EPS Growth TTM (YoY)-12.32%

Year-to-Date Return-60.85%

5-Day Price Return-5.32%

EPS Normalized (Annual)$0.20

ROA (5Y Avg)-11.53%

Net Profit Margin (Annual)13.43%

Month-to-Date Return-14.73%

EBITD / Share (Annual)$0.20

Operating Margin (Annual)12.58%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)33.12x

ROI (5Y Avg)-23.83%

P/E Excl Extra (TTM)12.32x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.19

P/TBV (Quarterly)3.29x

P/B Ratio (Annual)6.63x

Inventory Turnover (TTM)2.63x

Pretax Margin (TTM)13.19%

Book Value / Share (Annual)$0.96

Price vs S&P 500 (13W)-26.77%

Beta2.08x

P/FCF (Annual)14.91x

Revenue / Share (TTM)$1.56

ROE (TTM)20.50%

52-Week Low$2.46

vGradeC

gGradeC

mGradeD

vgmGradeC

NAGE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.01	$0.01	+233.00%(+$0.02)
Q1 2026	May 6, 2026	$0.06	$0.02	-62.47%(-$0.04)
Q4 2025	Mar 4, 2026	$0.02	$0.03	+65.57%(+$0.01)
Q3 2025	Nov 4, 2025	$0.01	$0.05	+233.33%(+$0.04)
Q2 2025	Aug 6, 2025	$0.01	$0.04	+499.70%(+$0.03)

NAGE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.27

4.25

Industry Peers — Pharmaceutical Preparations(21)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NAGENiagen Bioscience, Inc. Common Stock	C	C	D	1.5x	11.0%	64.2%	—	$2.49
RGCRegencell Bioscience Holdings Limited Ordinary Shares	—	—	B	—	—	—	—	$9.59
DFTXDefinium Therapeutics, Inc. Common Shares	—	—	B	—	—	—	—	$32.10
TRLVTrulieve Cannabis Corp.	B	C	A	1.7x	-3.9%	59.5%	—	$10.01
CRONCronos Group Inc. Common Share	C	B	A	6.6x	37.5%	46.5%	-50.0%	$3.21
TLRYTilray Brands, Inc. Common Stock	B	B	D	0.5x	15.9%	29.1%	—	$3.04
CGCCanopy Growth Corporation Common Shares	B	C	D	1.6x	6.8%	28.5%	—	$0.71
SNDLSundial Growers Inc. Common Shares	B	C	B	0.5x	-1.7%	26.2%	—	$1.25
GLASGlass House Brands Inc.	B	C	D	1.2x	-25.6%	30.8%	—	$3.19
USNAUSANA Health Sciences Inc	B	D	C	0.3x	5.7%	77.5%	-37.0%	$15.54
ACBAurora Cannabis Inc. Common Shares	B	D	B	1.3x	-18.9%	6.3%	—	$3.99
MDWDMediWound Ltd.	D	F	C	12.9x	-40.3%	15.5%	—	$11.85
FTLFFitLife Brands, Inc. Common Stock	B	C	C	0.8x	17.0%	36.5%	-20.0%	$8.39
BTMDBiote Corp. Class A Common Stock	A	D	D	0.2x	-7.8%	68.6%	-26.8%	$1.08
MTEXMannatech Inc.	B	D	B	0.1x	-5.0%	76.1%	-0.8%	$7.13
BONBon Natural Life Limited Class A Ordinary Shares	A	D	C	0.5x	-12.9%	22.1%	—	$1.14
NAIINatural Alternatives International Inc.	A	C	D	0.1x	9.8%	6.3%	—	$1.15
AKANAkanda Corp. Common Shares	C	F	F	12.2x	-63.1%	-60.5%	—	$1.20
IMCCIM Cannabis Corp. Common Shares	A	B	F	0.1x	12.7%	18.6%	—	$1.39
SNYRSynergy CHC Corp. Common Stock	A	C	F	0.0x	8.3%	65.4%	118.4%	$0.03
MEHAFunctional Brands, Inc. Common Stock	A	C	C	0.0x	—	53.7%	—	$0.00
TRUUVanEck Utilities TruSector ETF	—	—	B	—	—	—	—	$23.11

About Niagen Bioscience, Inc. Common Stock

Niagen Bioscience Inc develops NAD+-boosting therapeutics focused on extending healthspan and addressing age-related decline. The company's clinically proven flagship ingredient effectively raises NAD+ levels and serves as the foundation for its product portfolio. Leveraging precision science approaches, Niagen targets the growing healthy-aging market with evidence-based solutions.